Document:

EX-4.4

 Exhibit 4.4 

BY-LAW NO. 3 

ADVANCE NOTICE BY-LAW 

(Adopted by the Board of Directors of the Corporation with immediate effect on March 23, 2016)  

A by-law relating to the advance notice of nominations of directors of 

LIMINAL BIOSCIENCES INC. 

(hereinafter referred to as the “Corporation”)  

 
  

INTRODUCTION 
 The purpose of this Advance Notice By-Law (the “By-Law”) is to provide shareholders, directors and management of the Corporation with a clear framework for nominating directors. This By-Law fixes a deadline by which registered or beneficial owners of the common shares of the Corporation must submit director nominations to the Corporation prior to any annual or special meeting of shareholders
called for any purpose of which the election of directors is a matter specified in the notice of meeting, and sets forth the information to be provided and other procedures to be followed, in respect of such nomination. 

It is the position of the Corporation that this By-Law is in the best interests of the Corporation. This policy will
be subject to periodic review, and subject to the Act (as defined below), will reflect changes as required by securities regulatory authorities or stock exchanges and, at the discretion of the Board, amendments necessary to meet evolving industry
standards. 
 Article 1 

NOMINATION OF DIRECTORS 

Section 1.1    Subject only to the Canada Business Corporations Act (the “Act”), applicable securities laws
and the articles of the Corporation, only persons who are nominated in accordance with the procedures set out in this By-Law shall be eligible for election as directors to the board of directors (the
“Board”) of the Corporation. Nominations of persons for election to the Board may only be made at an annual meeting of shareholders, or at a special meeting of shareholders called for any purpose at which the election of directors
is a matter specified in the notice of meeting, as follows: 
  

	 	(a)	 by or at the direction of the Board or an authorized officer of the Corporation, including pursuant to a notice
of meeting; 

  

	 	(b)	 by or at the direction or request of one or more shareholders pursuant to a proposal made in accordance with
Section 137 of the Act or a requisition of shareholders made in accordance with Section 143 of the Act, as such provisions may be amended from time to time; or 

 

	 	(c)	 by any person entitled to vote at such meeting (a “Nominating Shareholder”), who: (A) is,
at the close of business on the date of giving notice provided for in Section 1.3 below and on the record date for notice of such meeting, either entered in the securities register of the Corporation as a holder of one or more shares carrying
the right to vote at such meeting or who beneficially owns shares that are entitled to be voted at such meeting; and (B) has given timely notice in proper written form as set forth in this By-Law.

 Section 1.2    For the avoidance of doubt, the foregoing Section 1.1 shall be the exclusive means for any
person to bring nominations for election to the Board before any annual or special meeting of shareholders of the Corporation. 

 Section 1.3    In addition to any other applicable requirement, for a nomination
made by a Nominating Shareholder to be timely notice (a “Timely Notice”), the Nominating Shareholder’s notice must be received by the corporate secretary of the Corporation at the principal executive offices of the
Corporation: 
  

	 	(a)	 in the case of an annual meeting of shareholders (including an annual and special meeting), not later than the
close of business on the thirtieth 30th day; provided, however, if the date (the “Notice Date”) on which the first public announcement made by the Corporation of the date of the
annual meeting is less than 50 days prior to the meeting date, not later than the close of business on the 10th day following the Notice Date; 

 

	 	(b)	 in the case of a special meeting (which is not also an annual meeting) of shareholders called for any purpose
which includes the election of directors to the Board, not later than the close of business on the 15th day following the day on which the first public announcement of the date of the special
meeting is made by the Corporation; 

 Section 1.4    To be in proper written form, a Nominating
Shareholder’s notice to the corporate secretary must comply with this Section and disclose or include, as applicable: 
  

	 	(a)	 as to each person whom the Nominating Shareholder proposes to nominate for election as a director (a
“Proposed Nominee”): 

  

	 	(i)	 their name, age, business and residential address; 

 

	 	(ii)	 the principal occupation, business or employment both presently and for the past five years;

  

	 	(iii)	 whether the Proposed Nominee is a “resident Canadian” within the meaning of the Act;

  

	 	(iv)	 the number of securities of each class of voting securities of the Corporation or any of its subsidiaries
beneficially owned, or controlled or directed, directly or indirectly, by the Proposed Nominee, as of the record date for the meeting of shareholders (if such date shall then have been made publicly available and shall have occurred) and as of the
date of such notice; 

  

	 	(v)	 a description of any relationships, agreements, arrangements, or understandings (including financial,
compensation or indemnity related) between the Proposed Nominee or any affiliates or associates of, or any person or entity acting jointly or in concert with, the Proposed Nominee or the Nominating Shareholder, in connection with the Proposed
Nominee’s nomination and election as director; and 

  

	 	(vi)	 any other information that would be required to be disclosed in a dissident proxy circular or other filings
required to be made in connection with the solicitation of proxies for election of directors pursuant to the Act or applicable securities law; 

  

	 	(b)	 as to each Nominating Shareholder giving the notice and each beneficial owner, if any, on whose behalf the
nomination is made: 

  

	 	(i)	 their name, business and residential address; 

	 	(ii)	 the number of securities of each class of voting securities of the Corporation or any of its subsidiaries
beneficially owned, or controlled or directed, directly or indirectly, by the Nominating Shareholder or any other person with whom the Nominating Shareholder is acting jointly or in concert with respect to the Corporation or any of its securities,
as of the record date for the meeting of shareholders (if such date shall then have been made publicly available and shall have occurred) and as of the date of such notice; 

 

	 	(iii)	 their interests in, or rights or obligations associated with, any agreement, arrangement or understanding, the
purpose or effect of which is to alter, directly or indirectly, the person’s economic interest in a security of the Corporation or the person’s economic exposure to the Corporation; 

 

	 	(iv)	 full particulars of any proxy, contract, arrangement, agreement or understanding pursuant to which such person,
or any of its affiliates or associates, or any person acting jointly or in concert with such person, has any interests, rights or obligations relating to the voting of any securities of the Corporation or the nomination of directors to the Board;

  

	 	(v)	 a representation and evidence that the Nominating Shareholder is a holder of record of securities of the
Corporation, or a beneficial owner, entitled to vote at such meeting, and intends to appear in person or by proxy at the meeting to propose such nomination; and 

 

	 	(vi)	 any other information relating to such person that would be required to be included in a dissident proxy
circular or other filings required to be made in connection with solicitations of proxies for election of directors pursuant to the Act or as required by applicable securities law; 

Reference to “Nominating Shareholder” in this Section 1.4 shall be deemed to refer to each shareholder that nominated or seeks to nominate a
person for election as director in the case of a nomination proposal where more than one shareholder is involved in making the nomination proposal. 

Section 1.5    If requested by the Corporation, the Nominating Shareholder shall update such information forthwith so that it is true
and correct as of the date that is ten (10) business days prior to the date of the meeting, or any adjournment or postponement thereof. 

Section 1.6    Any notice, or other document or information required to be given to the corporate secretary pursuant to this By-Law may only be given by personal delivery, facsimile transmission or by email (at such email address as may be stipulated from time to time by the corporate secretary for purposes of this notice), and shall be
deemed to have been received only at the time it is served by personal delivery to the corporate secretary at the address of the principal executive offices of the Corporation, email (at the address as aforesaid) or sent by facsimile transmission
(provided that receipt of confirmation of such transmission has been received); provided that if such delivery or electronic communication is made on a day which is a not a business day or later than 5:00 p.m. (Toronto time) on a day which is a
business day, then such delivery or electronic communication shall be deemed to have been made on the next following day that is a business day. 

Section 1.7    Additional Matters 
  

	(1)	 The chair of any meeting of shareholders of the Corporation shall have the power to determine whether any
proposed nomination is made in accordance with the provisions of this By-Law, and if any proposed nomination is not in compliance with such provisions, must declare that such defective nomination shall not be
considered at any meeting of shareholders. 

	(2)	 The Board may, in its sole discretion, waive any requirement of this
By-Law. 

  

	(3)	 For the purposes of this By-Law, “public announcement” means
disclosure in a press release disseminated by the Corporation through a national news service in Canada, or in a document filed by the Corporation for public access under its profile on the System of Electronic Document Analysis and Retrieval
(SEDAR) at www.sedar.com. 

  

	(4)	 This By-Law is subject to, and should be read in conjunction with, the
Act and the articles. If there is any conflict or inconsistency between any provision of the Act or the articles and any provision of this By-Law, the provision of the Act or the articles will govern.

 Article 2 

ANNUAL OR SPECIAL MEETINGS OF SHAREHOLDERS 

Section 2.1    No business may be transacted at an annual or special meeting of shareholders other than business that
is either (i) specified in the Corporation’s notice of meeting (or any supplement thereto) given by or at the direction of the Board, (ii) otherwise properly brought before the meeting by or at the direction of the Board, or
(iii) otherwise properly brought before the meeting by any shareholder of the Corporation who complies with the proposal procedures set forth in Section 2.2 below. 

Section 2.2    For business to be properly brought before a meeting by a shareholder of the Corporation, such shareholder must submit
a proposal to the Corporation for inclusion in the Corporation’s management proxy circular in accordance with the requirements of the Act; provided that any proposal that includes nominations for the election of directors shall also comply with
the requirements of Article 1.Exhibit
10.1

 

JOINT
VENTURE AGREEMENT

 

BETWEEN

 

NOVO
INTEGRATED SCIENCES INC.

(“NVOS”)

 

AND

 

HARVEST
GOLD FARMS INC.

(“HGF”)

 

FOR
THE DEVELOPMENT,

MANAGEMENT
AND OPERATION OF

HEMP
FARMING AND MEDICINAL CROPS

 

    	 		 

    	 

    

 

JOINT
VENTURE AGREEMENT

 

Dated
as of December 19, 2019

 

This
Joint Venture Agreement (the “Agreement”) is entered into between Novo Integrated Sciences Inc., a Nevada Corporation
with offices located at 11120 NE 2nd Street, Suite 200, Bellevue, Washington 98004, U.S.A (herein referred to as “NVOS”)
and Harvest Gold Farms Inc., a corporation organized under the laws of New Brunswick, Canada with offices located at 866 E. H.
Daigle Blvd, Grand Falls, New Brunswick, E3Z 3E8, Canada (herein referred to as “HGF”). NVOS and HGF may be referred
to herein collectively as the “Parties” and separately as a “Party.”

 

RECEITALS

 

WHEREAS,
NVOS is willing to assist in development, assist in management and purchase biomass resulting from open field farming for health-related
cash crops, in particular medicinal cannabis and industrial hemp;

 

WHEREAS,
NVOS is willing to develop and construct processing facilities as well as finished goods manufacturing and packaging facilities;

 

WHEREAS,
NVOS is willing to provide the Joint Venture access to its distribution pathways established either directly or indirectly through
NVOS or its wholly or partially owned subsidiaries;

 

WHEREAS,
NVOS is willing to establish reasonable commercial cost bases to product processing and packaging ensuring a profitable and fully
transparent Joint Venture;

 

WHEREAS,
NVOS is willing to utilize all applicable HGF tools and offerings for the purposes of developing a fully comprehensive North American
business platform;

 

WHEREAS,
HGF is willing to work towards a mutually acceptable Joint Venture;

 

WHEREAS,
HGF is willing to engage to its fullest potential in the licencing, employment harvesting, legal right consulting, business development
within its geographical jurisdiction;

 

WHEREAS,
HGF is willing assist in transport and distribution of raw and finished goods in both domestic and international jurisdictions;

 

WHEREAS,
HGF is willing to provide certified biomass to the JV on pre-determined, mutually agreed price per acre and participate on a net
revenue split of products offered to market directly or indirectly through NVOS channels;

 

NOW
THEREFORE, the Parties agree to sign this Agreement for the purposes of developing, managing and arranging medicinal farming projects
involving hemp and cannabis cash crops (hereinafter referred to as the “Primary Project”) under the following
terms set out in this Agreement for the noted project (herein, referred to as the “Primary Contract”).

 

    	 		 

    	 

    

 

 

ARTICLE
1 - DEFINITIONS AND INTERPRETATION

 

	1.1	For
    the purposes of this Agreement, unless the context otherwise requires, the following terms shall have the respective meanings
    set forth below and grammatical variations of such terms shall have corresponding meanings:

 

	 	(a)	“Action”
    means any legal action, suit, claim, investigation, hearing or proceeding, including any audit, claim or assessment for Taxes
    or otherwise.
	 	 	 
	 	(b)	“Agreement”
    means this Joint Venture Agreement, dated December 19, 2019.
	 	 	 
	 	(c)	“Company”
    means the Joint Venture entity which will be registered and incorporated in a Canadian jurisdiction with its operating name
    as Novo Earth Therapeutics Inc.
	 	 	 
	 	(d)	“Cost”
    means cost of goods sold as defined in the financials of the Primary Project.
	 	 	 
	 	(e)	“Effective
    Date” is the date of the most recent final signature on this Agreement.
	 	 	 
	 	(f)	“EPC”
    means engineering, procurement, construction contracts.
	 	 	 
	 	(g)	“HFG”
    means Harvest Gold Farms Inc.
	 	 	 
	 	(h)	“Joint
    Venture” means a business arrangement where NVOS and HGF have agreed to pool their resources for the purpose of the
    Primary Project.
	 	 	 
	 	(i)	“Law”
    means any domestic or foreign, federal, state, provincial, municipal or local law, statute, ordinance, code, rule, or regulation
    having the force of law.
	 	 	 
	 	(j)	“NHL”
    means Novo Healthnet Limited.
	 	 	 
	 	(k)	“NVOS”
    means Novo Integrated Sciences Inc.
	 	 	 
	 	(l)	“Parties”
    means collectively, Harvest Gold Farms Inc. and Novo Integrated Sciences Inc.
	 	 	 
	 	(m)	“Party”
    identifies, separately, either Harvest Gold Farms Inc. or Novo Integrated Sciences Inc.
	 	 	 
	 	(n)	“Primary
    Contract” means the terms set out in this agreement for the Primary Project.
	 	 	 
	 	(o)	“Primary
    Project” means this agreement that outlines the development, management and arranging of medicinal farming projects
    involving hemp and cannabis cash crops.
	 	 	 
	 	(p)	 “Tax(es)”
    means any federal, state, provincial, local or foreign tax, charge, fee, levy, custom, duty, deficiency, or other assessment
    of any kind or nature imposed by any Taxing Authority (including any income (net or gross), gross receipts, profits, windfall
    profit, sales, use, goods and services, ad valorem, franchise, license, withholding, employment, social security, workers
    compensation, unemployment compensation, employment, payroll, transfer, excise, import, real property, personal property,
    intangible property, occupancy, recording, minimum, alternative minimum, environmental or estimated tax), including any liability
    therefor as a transferee (including under Section 6901 of the Code or similar provision of applicable Law) or successor, as
    a result of Treasury Regulation Section 1.1502-6 or similar provision of applicable Law or as a result of any Tax sharing,
    indemnification or similar agreement, together with any interest, penalty, additions to tax or additional amount imposed with
    respect thereto.

 

    	 		 

    	 

    

 

	 	(q)	“Taxing
    Authority” means the Internal Revenue Service, the Canada Revenue Agency and any other Authority responsible for the
    collection, assessment or imposition of any Tax or the administration of any Law relating to any Tax.
	 	 	 
	 	(r)	“Tax
    Return” means any return, information return, declaration, claim for refund or credit, report or any similar statement,
    and any amendment thereto, including any attached schedule and supporting information, whether on a separate, consolidated,
    combined, unitary or other basis, that is filed or required to be filed with any Taxing Authority in connection with the determination,
    assessment, collection or payment of a Tax or the administration of any Law relating to any Tax.

 

	1.2	Interpretive
    Provisions. Unless the express context otherwise requires:

 

	 	(a)	the
    words “hereof,” “herein,” and “hereunder” and words of similar import, when used in this
    Agreement, shall refer to this Agreement as a whole and not to any particular provision of this Agreement;
	 	 	 
	 	(b)	terms
    defined in the singular shall have a comparable meaning when used in the plural, and vice versa;
	 	 	 
	 	(c)	references
    herein to a specific Section, Subsection, Recital, Schedule or Exhibit shall refer, respectively, to Sections, Subsections,
    Recitals, Schedules or Exhibits of this Agreement;
	 	 	 
	 	(d)	wherever
    the word “include,” “includes,” or “including” is used in this Agreement, it shall be
    deemed to be followed by the words “without limitation”;
	 	 	 
	 	(e)	references
    herein to any gender shall include each other gender;
	 	 	 
	 	(f)	references
    herein to any contract or agreement (including this Agreement) mean such contract or agreement as amended, supplemented or
    modified from time to time in accordance with the terms thereof;
	 	 	 
	 	(g)	with
    respect to the determination of any period of time, the word “from” means “from and including” and
    the words “to” and “until” each means “to and including”;
	 	 	 
	 	(h)	references
    herein to any Law or any license mean such Law or license as amended, modified, codified, reenacted, supplemented or superseded
    in whole or in part, and in effect from time to time; and
	 	 	 
	 	(i)	references
    herein to any Law shall be deemed also to refer to all rules and regulations promulgated thereunder.

 

    	 		 

    	 

    

 

ARTICLE
2 - ENTERPRISE NAME

 

	2.1	The
    Joint Venture has been registered and incorporated in a Canadian jurisdiction mutually acceptable to both parties and will
    be referred to as the “Company”, the Company shall have all the liabilities of the project in relation to finance
    and operation with HGF having no liability in relation to the project.

 

ARTICLE
3 - RELATIONSHIP OF PARTIES

 

	3.1	The
    parties will work in a Joint Venture relationship with NVOS providing the development and operation of the project including
    sales and HGF providing the land, farming expertise, biomass and necessary approvals for the development of the agricultural
    project.

 

ARTICLE
4 - OFFICE LOCATION

 

	4.1	The
    Company shall have an office in the NVOS head office location as well as an office on the Primary Project location and if
    necessary, offices in international jurisdictions for the purpose of sales and promotion.

 

ARTICLE
5 - START UP CAPITAL AND CONTRIBUTIONS

 

	5.1	Each
    of the Parties shall contribute to the start-up as follows:
	 	 
	5.1.1	NVOS

 

	 	●	Complete
    and finalize a business plan and layout plans, a detailed procurement project binder and an implementation and roll-out plan.
	 	●	Make
    arrangements for construction and financing options of any facilities required for the profitable farming of medicinal crops
    or related facilities.
	 	●	Direct
    project finance model and selection of EPC and management service providers.
	 	●	Arrange
    for product purchase contracts.

 

	5.1.2
    	HGF

 

	 	●	Will
    provide the land and approvals for greenhouse (if necessary), open field farming and other facilities as required.
	 	●	Arrange
    for all required titled land for greenhouses and outdoor agriculture platforms.
	 	●	Arrange
    for all building permits, environmental approvals and HGF internal approvals including confirmation of tax-free Company status
    for the duration of the proposal (if possible).
	 	●	Provide
    elite farming expertise for the purposes of maximizing potential profits, inclusive of harvesting techniques and process flow
    and engineering.

 

ARTICLE
6 - HGF AND NVOS COMMITMENTS SCHEDULE

 

	6.1	Upon
    execution of the proposal, HGF will provide necessary documentation for all land intended for use in the Primary Project including
    beneficial owners, addresses, and parcel size.

 

    	 		 

    	 

    

 

 

	6.2	Upon
    execution of the proposal, HGF will provide necessary documentation (allocated land) required for the completion of the construction
    and management package.
	 	 
	6.3	Harvesting
    schedule occurs as dictated by determined cash crop selection. Accompanying cash flow projections will be completed upon binding
    buyer contract receipt.

 

ARTICLE
7 - PRINCIPLE AND LINE OF CREDIT RETURNS

 

	7.1	Priority
    is given to all debt service requirements with principle pay-back schedule adherence based on cash flow actual conditions.
    Distribution to Parties as per agreement on a “last to issue” basis.

 

ARTICLE
8 - TERM OF AGREEMENT

 

	8.1	The
    initial term of this Agreement shall, unless sooner terminated by consent of all parties, expires in five (5) years from the
    date of Effective Date. NVOS and HGF may renew the Agreement within two (2) years of the expiry of the initial term upon mutual
    understanding.
	 	 
	8.2	It
    is understood that a subsequent renewal of a five (5) year term will be negotiated in good faith and shall carry terms very
    close to the original Agreement.
	 	 
	8.3	Both
    parties may enter into buyout negotiations with the other Party on terms agreeable to both Parties.

 

ARTICLE
9 - OBLIGATIONS OF NVOS

 

	9.1	To
    maintain all financial records of the Company and provide quarterly and annual reporting to all Company stakeholders. All
    records are kept under US GAAP compliance standards.
	 	 
	9.2	Assign
    and direct operational staff from onset to agreement termination.
	 	 
	9.3	To
    remunerate HGF on the basis of thirty percent (30%) of net Company income basis on an annual basis commencing 12 months after
    the first full 12-month revenue period.
	 	 
	9.4	To
    purchase product from the Company at a price of cost plus five percent (5%).
	 	 
	9.5	To
    issue two (2) million NVOS common stock upon successful target of twenty-five million dollars ($25M) of net profit achieved
    by the Company each fiscal year. NVOS common stock will be delivered to HGF via Novo Healthnet Limited (“NHL”)
    exchangeable preferred shares. All parties understand NVOS is a U.S. reporting publicly traded corporation and that any NVOS
    common shares issued, from exchanging the NHL exchangeable preferred shares, will be provided under the guiding U.S. rules
    and regulations. Furthermore, all parties understand these shares will carry the same rights and conditions, with no special
    terms or conditions, as all NVOS common shares authorized for issue under the companies’ Nevada Articles of Incorporation.
    Any NVOS common stock issued to HGF, on or after the date hereof, is subject to pro-rata adjustment in the event that NVOS
    shall, prior to the issuance date, approve any forward stock split, reverse stock split or other capitalization re-structure.

 

    	 		 

    	 

    

 

ARTICLE
10 - OBLIGATIONS OF HGF

 

	10.1	To
    assist the Company in any way deemed necessary by the Company in the marketing and sales of all cash crops associated to the
    Primary Project both domestically and internationally.
	 	 
	10.2	To
    maintain positive relations with agencies (government and environmental) ensuring continuing land use and development.
	 	 
	10.3	To
    promote and maintain positive public relations activities ensuring positive Company public opinion.
	 	 
	10.4	To
    grow medicinal agriculture crop at the highest standard, subject to independent third party biomass testing.
	 	 
	10.5	To
    grow in the most profitable manner while maintaining the standards of excellence required to maintain elite status.
	 	 
	10.6	To
    provide a minimum of seven thousand (7000) acres for the Primary Project to be identified by each individual lot, including
    size, and its placement in the annual rotation as per SCHEDULE A.

 

ARTICLE
11 - MANAGEMENT PERSONNEL

 

	11.1	All
    staffing, including but not limited to, management, specialized or general labor requirements for farming will be the sole
    responsibility of HGF.

 

ARTICLE
12 - DIVIDEND DISTRIBUTIONS

 

	12.1	The
    distribution will be based on NVOS audited review and will be made within three months of annual considerations on the basis
    of a seventy percent (70%) of net profit to NVOS and thirty percent (30%) of net profit to HGF.
	 	 
	12.2	The
    distribution will be based on NVOS audited review and will be made within three months of annual considerations.

 

ARTICLE
13 - CURRENCY

 

	13.1	Except
    where otherwise expressly provided, all amounts of monies referenced are in US dollars.

 

ARTICLE
14 - BANKING AND ACCOUNTING

 

	14.1	The
    Company will have a segregated bank account controlled by NVOS for general operating expenses and a segregated investment
    account for passive short-term secured investments.

 

ARTICLE
15 - FINANCIAL STATEMENTS

 

	15.1	The
    Company will prepare quarterly statements for review by the Parties, released on the 15th day of each subsequent quarter.

 

    	 	 	 

    	 

    

 

	15.2	The
    Company’s audited annual filing will be prepared in accordance to NVOS requirements for the purposes of consolidation
    on a US GAAP accounting basis.
	 	 
	15.3	The
    Company’s fiscal year is September 1 through August 31. 

 

ARTICLE
16 - TAXES

 

	16.1	The
    Company will ensure timely remittance of all tax liabilities and ensure specific adherence to any specific tax considerations.
    HGF will ensure maximum tax reduction and where possible elimination of any tax consideration.

 

ARTICLE
17 - PRESERVATION OF RECORDS

 

	17.1	All
    company records will be kept for a minimum of five (5) years unless otherwise required by federal or provincial law.

 

ARTICLE
18 - ASSIGNMENT BY NVOS

 

	18.1	During
    the term of this agreement NVOS shall have the right to assign, transfer or sell all or part of its interest in the agreement
    upon the terms and conditions herein, subject only to prior written notice to HGF.

 

ARTICLE
19 - ASSIGNMENT BY HGF

 

	19.1	During
    the term of this agreement HGF shall have the right, upon written approval of NVOS, to assign, transfer or sell all or part
    of their interest in this agreement.

 

ARTICLE
20 - BEST EFFORTS

 

	20.1	NVOS
    and HGF covenant and agree to make their best efforts to fully develop the Primary Projects as well as all projects associated
    to this agreement as per this agreement at all times faithfully, honestly and diligently perform or cause to be performed
    their obligations hereunder and to continuously exert best efforts to promote and enhance the business and in that regards
    they hereby covenant and agree, so long as this Agreement shall remain in effect, to operate the business, as to preserve,
    maintain and enhance the reputation of NVOS and HGF through the Company.

 

ARTICLE
21 - DISPUTES

 

	21.1	The
    Parties shall negotiate in good faith and make every effort to settle any dispute, or claim, that may arise out of, or relate
    to, the Agreement. If agreement cannot be reached, an aggrieved Party shall, if he intends to proceed further in terms of
    Section 21.2 hereof, advise all other Parties in writing that negotiations have failed and that he intends to refer the matter
    to mediation in terms of Section 21.2.
	 	 
	21.2	Not
    earlier than ten (10) working days after having advised the other Party, in terms of Section 21.2, that negotiations in regard
    to a dispute have failed, an aggrieved Party may require that the dispute be referred, without legal representation, to mediation
    by a single mediator. The mediator shall be selected by agreement between the Parties. The costs of the mediation shall be
    borne equally by the Parties.

 

    	 	 	 

    	 

    

 

	 	The
    mediator shall convene a hearing of the Parties and may hold separate discussions with either Party and shall assist the Parties
    in reaching a mutually acceptable settlement of their differences through means of reconciliation, interpretation, clarification,
    suggestion and advice. The Parties shall record such agreement in writing and thereafter they shall be bound by such agreement.
	 	 
	 	The
    mediator is authorised to end the mediation process whenever in his opinion further efforts at mediation would not contribute
    to a resolution of the dispute between the Parties.
	 	 
	21.3	Where
    a dispute or claim is not resolved by mediation, it shall be referred to arbitration by a single arbitrator to be selected
    by agreement between the Parties. The Party requiring referral to arbitration shall notify the other Party, in writing, thereof,
    not later than thirty (30) calendar days after the mediator has expressed his opinion, failing which the mediator’s
    opinion shall be deemed to have been accepted by the Parties and shall be put into effect.
	 	 
	 	Arbitration
    shall be conducted in accordance with the provisions of the Arbitration Act No. 42 of 1965, as amended, and in accordance
    with such procedure as may be agreed by the Parties or, failing such agreement, in accordance with the rules for the Conduct
    of Arbitrations published by the Association of Arbitrators and current at the date that the arbitrator is appointed.
	 	 
	 	The
    decisions of the arbitrator shall be final and binding on the Parties, shall be carried into immediate effect and, if necessary,
    be made an order of any court of competent jurisdiction.

 

ARTICLE
22 - INDEMNIFICATION

 

	22.1	The
    Parties agree to mutually defend, indemnify and save one another harmless from and against any claims, demands, actions, losses,
    damages, costs, charges, liabilities and any expenses, including legal fees of whatever kind arising out of or in connection
    with each parties’ activities conducted pursuant to this Agreement.

 

ARTICLE
23 - CONFORMITY WITH LAWS

 

	23.1	In
    this Agreement, the singular includes the plural and the masculine includes the feminine and neuter and vice versa unless
    the context otherwise requires.
	 	 
	23.2	If
    any provision or part of any provision in this Agreement is void for any reason or found to be unenforceable, it may be severed
    without affecting the validity and enforceability of the balance of the Agreement.
	 	 
	23.3	This
    Agreement binds and benefits the parties and their respective heirs, executors, administrators, personal representatives,
    successors and assigns.
	 	 
	23.4	This
    Agreement contains the sole and entire agreement between the parties and supersedes any and all other agreements, both verbal
    and written, between them.

 

    	 	 	 

    	 

    

 

	23.5	The
    parties agree that neither of them has made any representations with respect to the subject matter of this Agreement, or any
    representations inducing the execution and delivery hereof, except such representations as are specifically set forth herein.

 

ARTICLE
24 - CONFIDENTIALITY

 

	24.1	The
    parties shall keep confidential all business terms and conditions of this Agreement and neither shall release such information
    to any other party without the express written consent of the other, in the case of NVOS, it is understood that NVOS will
    be filing this Agreement with the Security Exchange Commission of the United States of America in a matter compliant to publicly
    listed company rules.

 

ARTICLE
25 - ENTIRE AGREEMENT

 

	25.1	No
    waiver or modification of this Agreement or of any covenant, condition or limitation herein contained shall be valid unless
    in writing and duly executed by the party to be charged therewith.
	 	 
	25.2	Furthermore,
    no evidence of any waiver or modification shall be offered or received in evidence in any proceeding, arbitration, or litigation
    between the parties arising out of or affecting this agreement, or the rights or obligations of any party hereunder, unless
    such waiver or modification is in writing, duly executed as aforesaid.
	 	 
	25.3	The
    provisions of this paragraph may not be waived as set forth herein.

 

[Signatures
Appear on Following Page]

 

    	 	 	 

    	 

    

 

ARTICLE
26 - AFFIRMATION AND EXECUTION

 

	 	Novo Integrated Sciences Inc.
	 	 	 
	 	By:	/s/
    Robert Mattacchione
	 	Name:	Robert
    Mattacchione
	 	Title:	CEO
	 	 	 
	 	Date:
    	December
    19, 2019
	 	 	 
	 	Address for Notices:
	 	119 Westcreek Drive Unit 1
	 	Woodbridge, Ontario, Canada, L4L 9N6
	 	Email: xxxxxxxxx@xxxxxxx.com
	 	 
	 	Harvest Gold Farms Inc.
	 	 	 
	 	By:	/s/
    Michael Scully
	 	Name:
    	Michael
    Scully, BBA J.D.
	 	Title:	President
	 	 	 
	 	Date:
    	December
    19, 2019
	 	 	 
	 	Address for Notices:
	 	866 E. H. Daigle Blvd.
	 	Grand Falls, New Brunswick, Canada, E3Z 3E8
	 	Email: xxxxxxxxx@gmail.com

 

    	 	 	 

    	 

    

 

 

SCHEDULE
A

 

Acreage
Identification for the Primary Project

 

Disclosed
in certificate of Robert Mattacchione, dated December 18, 2019.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00302-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00302-of-00352.parquet"}]]